Medinova Diagnostic Services Ltd
BSE:526301
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (27.9), the stock would be worth ₹43.45 (0% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27.9 | ₹43.45 |
0%
|
| 3-Year Average | 27.9 | ₹43.45 |
0%
|
| 5-Year Average | 26.1 | ₹40.65 |
-6%
|
| Industry Average | 83 | ₹129.25 |
+197%
|
| Country Average | 49.7 | ₹77.5 |
+78%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Medinova Diagnostic Services Ltd
BSE:526301
|
433.7m INR | 27.9 | 20.3 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
104.3B USD | 12.3 | 59 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
72.9B EUR | 12.6 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
74.5B USD | 0 | 12.5 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.2B EUR | -25.1 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.4B EUR | 13.9 | 22.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.4B USD | 23.7 | 21 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21B USD | 627.8 | 24 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 6.7 | 11 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.4B USD | 69.1 | -27.5 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 6 | 13.9 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 27.4 |
| Median | 49.7 |
| 70th Percentile | 92 |
| Max | 57 010.1 |
Other Multiples
Medinova Diagnostic Services Ltd
Glance View
Medinova Diagnostic Services Ltd. is engaged in the business of medical or clinical services. The company is headquartered in Hyderabad, Telangana. The firm provides a range of diagnostic services spanning pathological investigations, radiology and imaging, conventional, specialized lab services and diagnostic cardiology. The company offers various services ranging from an ordinary blood test to a computerized tomography (CT)/ magnetic resonance imaging (MRI) scan. Its investigations are classified are lab, radiology, imageology, cardiology and gastroscopy. The company has built up various profiles to meet various requirements of patients, such as Master Health Check Up, Executive Health Check Up, Well Woman Check Up, Cardiac Profile and Diabetic Profile. The company has designed various health schemes and packages to provide concessional treatment. Its services also include corporate services, home visits, ambulance services and health camps. The firm's diagnostic centers are set up under the franchise arrangement.
